Google
TEM 株価分析 — TEMPUS AI, INC. CLASS A COMMON STOCK (Healthcare >> Health Information Services)
TEM に関するよくある質問
TEMのROE（自己資本利益率）は？
TEMPUS AI, INC. CLASS A COMMON STOCKのROEは-72.74%です。
TEMの配当利回りは？
TEMPUS AI, INC. CLASS A COMMON STOCKの配当利回りは0.00%です。
TEMの品質スコア（Quality Score）は？
当社のAIはTEMの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
TEMは今が買い時ですか？
当社AIのタイミングスコアは100点中28点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
TEMはどのセクターに属しますか？
TEMPUS AI, INC. CLASS A COMMON STOCKはHealthcare >> Health Information Servicesセクターに分類されます（NASDAQ市場）
TEM AI Analysis Summary
Our AI summary for TEM: TEMPUS AI, INC. CLASS A COMMON STOCK (NASDAQ), Healthcare >> Health Information Services sector. The stock currently trades at a P/E of 0.00, ROE of -72.74%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 43.87
Price
-0.42
(-0.95%)
Day Change
|
|
|---|
TEM, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 43.87 |
| PBV / Sector |
19.15 / 6.33
|
| Earning Per Share | -1.67 |
| PE / Sector |
N/A / 46.50
|
| PEG or PE/Growth / Sector |
N/A / -0.41
|
| Average 1M Daily Value |
251.29 M
GREAT
|
| Average 1W Daily Value |
259.31 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:34 |
| Symbol | TEM |
| Name | TEMPUS AI, INC. CLASS A COMMON STOCK |
| Sector | Healthcare >> Health Information Services |
| Market | NASDAQ |
| Listed Shares | 175.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 7,974.89 / 4,079.00 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 600 West Chicago Avenue, Chicago, IL, United States, 60654
Phone: 800 976 5448
Website: https://www.tempus.com
Employees: 3,800
Description: Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Health Information Services
Click a bubble to view stock details · Bubble size represents market capitalization share
